Cargando…
Natural and Induced Humoral Responses to MUC1
MUC1 is a membrane-tethered mucin expressed on the ductal cell surface of glandular epithelial cells. Loss of polarization, overexpression and aberrant glycosylation of MUC1 in mucosal inflammation and in adenocarcinomas induces humoral immune responses to the mucin. MUC1 IgG responses have been ass...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759187/ https://www.ncbi.nlm.nih.gov/pubmed/24212946 http://dx.doi.org/10.3390/cancers3033073 |
_version_ | 1782477219912744960 |
---|---|
author | von Mensdorff-Pouilly, Silvia Moreno, Maria Verheijen, René H. M. |
author_facet | von Mensdorff-Pouilly, Silvia Moreno, Maria Verheijen, René H. M. |
author_sort | von Mensdorff-Pouilly, Silvia |
collection | PubMed |
description | MUC1 is a membrane-tethered mucin expressed on the ductal cell surface of glandular epithelial cells. Loss of polarization, overexpression and aberrant glycosylation of MUC1 in mucosal inflammation and in adenocarcinomas induces humoral immune responses to the mucin. MUC1 IgG responses have been associated with a benefit in survival in patients with breast, lung, pancreatic, ovarian and gastric carcinomas. Antibodies bound to the mucin may curb tumor progression by restoring cell-cell interactions altered by tumor-associated MUC1, thus preventing metastatic dissemination, as well as counteracting the immune suppression exerted by the molecule. Furthermore, anti-MUC1 antibodies are capable of effecting tumor cell killing by antibody-dependent cell-mediated cytotoxicity. Although cytotoxic T cells are indispensable to achieve anti-tumor responses in advanced disease, abs to tumor-associated antigens are ideally suited to address minimal residual disease and may be sufficient to exert adequate immune surveillance in an adjuvant setting, destroying tumor cells as they arise or maintaining occult disease in an equilibrium state. Initial evaluation of MUC1 peptide/glycopeptide mono and polyvalent vaccines has shown them to be immunogenic and safe; anti-tumor responses are scarce. Progress in carbohydrate synthesis has yielded a number of sophisticated substrates that include MUC1 glycopeptide epitopes that are at present in preclinical testing. Adjuvant vaccination with MUC1 glycopeptide polyvalent vaccines that induce strong humoral responses may prevent recurrence of disease in patients with early stage carcinomas. Furthermore, prophylactic immunotherapy targeting MUC1 may be a strategy to strengthen immune surveillance and prevent disease in subjects at hereditary high risk of breast, ovarian and colon cancer. |
format | Online Article Text |
id | pubmed-3759187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-37591872013-09-04 Natural and Induced Humoral Responses to MUC1 von Mensdorff-Pouilly, Silvia Moreno, Maria Verheijen, René H. M. Cancers (Basel) Review MUC1 is a membrane-tethered mucin expressed on the ductal cell surface of glandular epithelial cells. Loss of polarization, overexpression and aberrant glycosylation of MUC1 in mucosal inflammation and in adenocarcinomas induces humoral immune responses to the mucin. MUC1 IgG responses have been associated with a benefit in survival in patients with breast, lung, pancreatic, ovarian and gastric carcinomas. Antibodies bound to the mucin may curb tumor progression by restoring cell-cell interactions altered by tumor-associated MUC1, thus preventing metastatic dissemination, as well as counteracting the immune suppression exerted by the molecule. Furthermore, anti-MUC1 antibodies are capable of effecting tumor cell killing by antibody-dependent cell-mediated cytotoxicity. Although cytotoxic T cells are indispensable to achieve anti-tumor responses in advanced disease, abs to tumor-associated antigens are ideally suited to address minimal residual disease and may be sufficient to exert adequate immune surveillance in an adjuvant setting, destroying tumor cells as they arise or maintaining occult disease in an equilibrium state. Initial evaluation of MUC1 peptide/glycopeptide mono and polyvalent vaccines has shown them to be immunogenic and safe; anti-tumor responses are scarce. Progress in carbohydrate synthesis has yielded a number of sophisticated substrates that include MUC1 glycopeptide epitopes that are at present in preclinical testing. Adjuvant vaccination with MUC1 glycopeptide polyvalent vaccines that induce strong humoral responses may prevent recurrence of disease in patients with early stage carcinomas. Furthermore, prophylactic immunotherapy targeting MUC1 may be a strategy to strengthen immune surveillance and prevent disease in subjects at hereditary high risk of breast, ovarian and colon cancer. Molecular Diversity Preservation International (MDPI) 2011-07-29 /pmc/articles/PMC3759187/ /pubmed/24212946 http://dx.doi.org/10.3390/cancers3033073 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review von Mensdorff-Pouilly, Silvia Moreno, Maria Verheijen, René H. M. Natural and Induced Humoral Responses to MUC1 |
title | Natural and Induced Humoral Responses to MUC1 |
title_full | Natural and Induced Humoral Responses to MUC1 |
title_fullStr | Natural and Induced Humoral Responses to MUC1 |
title_full_unstemmed | Natural and Induced Humoral Responses to MUC1 |
title_short | Natural and Induced Humoral Responses to MUC1 |
title_sort | natural and induced humoral responses to muc1 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759187/ https://www.ncbi.nlm.nih.gov/pubmed/24212946 http://dx.doi.org/10.3390/cancers3033073 |
work_keys_str_mv | AT vonmensdorffpouillysilvia naturalandinducedhumoralresponsestomuc1 AT morenomaria naturalandinducedhumoralresponsestomuc1 AT verheijenrenehm naturalandinducedhumoralresponsestomuc1 |